title: Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.
authors.forename: D Mark
authors.initials: DM
authors.lastname: Davies
authors.forename: Simon R
authors.initials: SR
authors.lastname: Johnson
authors.forename: Anne E
authors.initials: AE
authors.lastname: Tattersfield
authors.forename: J Chris
authors.initials: JC
authors.lastname: Kingswood
authors.forename: Jane A
authors.initials: JA
authors.lastname: Cox
authors.forename: Deborah L
authors.initials: DL
authors.lastname: McCartney
authors.forename: Tim
authors.initials: T
authors.lastname: Doyle
authors.forename: Frances
authors.initials: F
authors.lastname: Elmslie
authors.forename: Anand
authors.initials: A
authors.lastname: Saggar
authors.forename: Petrus J
authors.initials: PJ
authors.lastname: de Vries
authors.forename: Julian R
authors.initials: JR
authors.lastname: Sampson
mesh_terms: D018207:Angiomyolipoma / Q000188:drug therapy* / Q000209:etiology; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology; D018192:Lymphangioleiomyomatosis / Q000150:complications*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011494:Protein Kinases / Q000378:metabolism; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases; D014402:Tuberous Sclerosis / Q000150:complications*
chemical_list: D007166:Immunosuppressive Agents; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus